$161.76 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter

Analysts expect Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report $161.76 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Halozyme Therapeutics’ earnings, with the lowest sales estimate coming in at $147.57 million and the highest estimate coming in at $187.15 million. Halozyme Therapeutics posted sales of $39.00 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 314.8%. The business is scheduled to announce its next earnings report after the market closes on Tuesday, February 20th.

On average, analysts expect that Halozyme Therapeutics will report full-year sales of $161.76 million for the current year, with estimates ranging from $314.20 million to $314.30 million. For the next fiscal year, analysts anticipate that the company will post sales of $138.73 million per share, with estimates ranging from $123.20 million to $154.26 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Halozyme Therapeutics.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The firm had revenue of $63.73 million during the quarter, compared to the consensus estimate of $58.95 million. During the same period in the previous year, the company posted ($0.23) earnings per share. The company’s revenue for the quarter was up 100.1% on a year-over-year basis.

A number of brokerages have issued reports on HALO. Zacks Investment Research downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, December 25th. Deutsche Bank set a $21.00 target price on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 24th. Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $20.00 target price on the stock. BidaskClub upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Finally, Barclays cut shares of Halozyme Therapeutics from an “overweight” rating to a “hold” rating and boosted their target price for the company from $16.00 to $19.00 in a research note on Wednesday, November 22nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. Halozyme Therapeutics currently has a consensus rating of “Hold” and an average target price of $19.25.

Shares of Halozyme Therapeutics (HALO) opened at $18.37 on Friday. Halozyme Therapeutics has a 52-week low of $11.41 and a 52-week high of $21.13. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.46 and a quick ratio of 3.37. The stock has a market cap of $2,540.00, a PE ratio of -27.01 and a beta of 1.98.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cornerstone Capital Management Holdings LLC. boosted its stake in Halozyme Therapeutics by 0.7% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 57,963 shares of the biopharmaceutical company’s stock valued at $742,000 after acquiring an additional 396 shares during the last quarter. Amalgamated Bank lifted its stake in shares of Halozyme Therapeutics by 5.3% during the 2nd quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 705 shares in the last quarter. Prudential Financial Inc. lifted its stake in shares of Halozyme Therapeutics by 8.7% during the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 940 shares in the last quarter. Parametric Portfolio Associates LLC lifted its stake in shares of Halozyme Therapeutics by 4.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 55,012 shares of the biopharmaceutical company’s stock valued at $705,000 after buying an additional 2,228 shares in the last quarter. Finally, M&T Bank Corp lifted its stake in shares of Halozyme Therapeutics by 7.5% during the 2nd quarter. M&T Bank Corp now owns 34,362 shares of the biopharmaceutical company’s stock valued at $441,000 after buying an additional 2,405 shares in the last quarter. Hedge funds and other institutional investors own 84.41% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/04/161-76-million-in-sales-expected-for-halozyme-therapeutics-inc-halo-this-quarter.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply